KK (Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AbbVie GK, Novartis Pharma K.K., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Celgene Corporation/Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd.), KI (Celgene Corporation/Bristol-Myers Squibb Co., MSD K.K., AstraZeneca, AbbVie GK, Eisai Co., Ltd., Incyte Japan, Solasia Pharma K.K., Novartis Pharma K.K., Bayer Yakuhin, Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Yakult Honsha Co., Ltd., Kyowa Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., BeiGene, Inc., Genmab K.K., Otsuka Pharmaceutical Co., Ltd., Loxo Oncology), YM (Kyowa Kirin Co, Ltd.), IM (Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Shionogi Co., Ltd., Teijin Pharma Ltd., Boehringer Ingelheim, Sanofi K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., MSD K.K., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Japan Blood Products Organization, Nihon Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., AbbVie GK, Taiho Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., CSL Behring, Mundipharma K.K., Ayumi Pharmaceutical Corporation, Eli Lilly Japan K.K., Actelion Pharmaceuticals Japan Ltd., Amgen Biopharma K.K.), KA (Takeda Pharmaceutical Co., Ltd.) and JS (Astellas Pharma Inc, Celgene Corporation/Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., AstraZeneca, Bayer Yakuhin, Ltd., SymBio Pharmaceuticals Ltd. Yakult Honsha Co., Ltd.) have grants or contracts from each entity. KK (AbbVie GK, AstraZeneca, Celgene Corporation/Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Novartis Pharma K.K., Daiichi Sankyo Co., Ltd.), KI (Solasia Pharma K.K., Novartis Pharma K.K., Bayer Yakuhin, Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Yakult Honsha Co., Ltd.), IM (Otsuka Pharmaceutical Co., Ltd.) and JS (Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd.) are consultants for each entity. KK (Takeda Pharmaceutical Co., Ltd., MSD K.K., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Celgene Corporation/Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd., Mundipharma K.K., Sumitomo Dainippon Pharma Co., Ltd.), KI (Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., AstraZeneca, Novartis Pharma K.K., Celgene Corporation/Bristol-Myers Squibb Co., Kyowa Kirin Co., Ltd., AbbVie GK, Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Daiichi Sankyo Co., Ltd., Kyorin Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co., Ltd., Allergan Japan K.K., Fujifilm Toyama Chemical Co., Ltd.), MN (Bristol-Myers-Squibb Co., SymBio Pharmaceuticals Ltd., Eisai Co., Ltd., AbbVie GK, Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Nippon Shinyaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca, Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd.), HS (Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Sanofi K.K., AstraZeneca, SymBio Pharmaceuticals Ltd., Celgene Corporation/Bristol-Myers Squibb Co., AbbVie GK, Fujimoto Pharmaceutical Corporation), YM (Kyowa Kirin Co., Ltd.), KY (Chugai Pharmaceutical Co., Ltd.), TM (AbbVie GK, Otsuka Pharmaceutical Co., Ltd., MSD K.K., Janssen Pharmaceutical K.K., Astellas Pharma Inc.), SR (Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K.), IM (Celgene Corporation/Bristol-Myers Squibb Co., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd.), KA (Takeda Pharmaceutical Co., Ltd.) and JS (AbbVie GK, Astellas Pharma Inc., AstraZeneca, Celgene Corporation/Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., CSL-Behring, Sumitomo Dainippon Pharma Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd. SymBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co., Ltd.) have directly payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from each entity. KI (Takeda Pharmaceutical Co., Ltd., Celgene Corporation/Bristol-Myers Squibb Co., Genmab K.K., AstraZeneca, AbbVie GK) and HS (Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Fujimoto Pharmaceutical Corporation) are assigned as each entity's advisory board. HS (Kyowa Kirin Co., Ltd.) and JS (Eisai Co., Ltd.) have all support for the present manuscript. UT, YM, JI, TT, TY and YK have no COI to disclose. The current affiliation for K.I. is Department of Hematology, National Cancer Centre Hospital, Tokyo; H.S. is Department of Hematology, National Hospital Organization Osaka National Hospital, Osaka; K.Y. is Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima; U.T. is Department of Diagnostic Radiology, Tokyo Medical and Dental University, Tokyo; T.M. is Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa; Y.K. is Director, Sumitomo Hospital, Osaka; J.S. is Department of Hematology, Koga Community Hospital, Yaizu, Japan.